Zacks: Brokerages Anticipate Iovance Biotherapeutics Inc (NASDAQ:IOVA) to Post -$0.35 Earnings Per Share
Equities analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to announce ($0.35) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.43). Iovance Biotherapeutics posted earnings of ($0.36) per share during the same quarter last year, which indicates a positive year over year growth rate of 2.8%. The business is expected to announce its next earnings report on Tuesday, November 5th.
According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.60) to ($0.84). For the next year, analysts anticipate that the business will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.41) to ($0.59). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Iovance Biotherapeutics.
Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.09).
Several hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $29,000. Edge Wealth Management LLC boosted its holdings in shares of Iovance Biotherapeutics by 20.2% during the 2nd quarter. Edge Wealth Management LLC now owns 8,414 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 1,414 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Iovance Biotherapeutics by 58.6% during the 4th quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 3,000 shares in the last quarter. Aperio Group LLC bought a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $86,000. Finally, Swiss National Bank boosted its holdings in shares of Iovance Biotherapeutics by 2.3% during the 2nd quarter. Swiss National Bank now owns 195,200 shares of the biotechnology company’s stock valued at $4,786,000 after buying an additional 4,400 shares in the last quarter. Hedge funds and other institutional investors own 95.67% of the company’s stock.
Shares of Iovance Biotherapeutics stock traded down $0.50 on Thursday, hitting $20.02. The stock had a trading volume of 1,322,889 shares, compared to its average volume of 1,447,800. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.14 and a current ratio of 12.15. Iovance Biotherapeutics has a one year low of $7.26 and a one year high of $26.59. The firm has a market cap of $2.52 billion, a PE ratio of -15.76 and a beta of 1.81. The firm has a 50-day moving average of $23.98.
About Iovance Biotherapeutics
Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.
Featured Article: Trading signals using Bollinger bands
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.